Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Press release

E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS; SETS FULL YEAR 2026 OUTLOOK

elevancehealth.jpg

•4Q 2025 operating revenue of $49.3 billion; FY 2025 of $197.6 billion •4Q 2025 diluted EPS1 of $2.47; adjusted diluted EPS2 of $3.33 •FY 2025 diluted EPS1 of $25.21; adjusted diluted EPS2 of $30.29 •Projected FY 2026 GAAP diluted EPS1 to be at least $22.30 •Projected FY 2026 adjusted diluted EPS2 to be at least $25.50 •Returned $4.1 billion of capital to shareholders in 2025 •Reaffirming long-term earnings algorithm; recalibrating segment margin targets Indianapolis, IN - January 28, 2026 - Elevance Health, Inc. (NYSE: ELV) reported fourth quarter and full year 2025 results.

"Elevance Health delivered fourth quarter results in line with our outlook, reflecting disciplined execution in a dynamic environment. As we enter 2026, our focus is on advancing affordability and making healthcare easier to access and navigate for the members we serve. Through pricing discipline and targeted investments, we are strengthening the earnings power of our diversified platform and remain confident in our ability to return to at least 12% adjusted EPS growth in 2027."

Gail K. Boudreaux

President and Chief Executive Officer

1.Earnings per diluted share ("EPS").

2.Refer to GAAP reconciliation tables on pages 13 and 14 herein for reconciliation of GAAP to adjusted measures.

image1.jpg

Elevance Health
Consolidated Enterprise Highlights
(Unaudited)
(In billions)Three Months EndedTwelve Months Ended
December 31, 2025December 31, 2024December 31, 2025December 31, 2024

Operating Revenue1

$49.3$45.0$197.6$175.2

Operating Gain1,2

$0.3$0.7$7.2$7.9

Adjusted Operating Gain1,3

$0.4$0.8$7.5$9.3

Operating Margin1

0.6%1.5%3.6%4.5%

Adjusted Operating Margin1,3

0.8%1.9%3.8%5.3%

1.See “Basis of Presentation” on page 5 herein.

2.Operating Gain for the three and twelve months ended December 31, 2025, and December 31, 2024, includes items that are excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.

3.Adjusted Operating Gain for the three and twelve months ended December 31, 2025, and December 31, 2024, excludes items that are excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.

Operating revenue was $49.3 billion in the fourth quarter of 2025, an increase of $4.3 billion, or 10 percent compared to the prior year quarter. Operating revenue was $197.6 billion in 2025, an increase of $22.4 billion, or 13 percent. The increase in revenue for the quarter and year was driven by higher premium yields in our Health Benefits segment, contributions from acquisitions, and growth in Medicare Advantage membership, partially offset by membership attrition in our Medicaid business.

The benefit expense ratio was 93.5 percent in the fourth quarter, an increase of 110 basis points compared to the prior year period, reflecting higher medical cost trend primarily in our Affordable Care Act health plans and heightened Medicare Part D seasonality driven by Inflation Reduction Act changes. For the year, our benefit expense ratio was 90.0 percent, an increase of 150 basis points year over year, driven by elevated medical cost trends.

Days in Claims Payable was 41.3 days as of December 31, 2025, a decrease of 0.1 days from September 30, 2025, and a decrease of 1.9 days compared to December 31, 2024.

The operating expense ratio was 11.0 percent in the fourth quarter and 10.6 percent for the full year. On an adjusted basis, the corresponding operating expense ratios were 10.8 percent and 10.5 percent. We maintained expense discipline while investing to support and strengthen our workforce, scale Carelon's capabilities, and accelerate technology adoption across the enterprise.

Cash Flow & Balance Sheet

Operating cash flow was $4.3 billion in 2025, approximately 0.8 times GAAP net income. As of December 31, 2025, cash and investments at the parent company totaled approximately $2.6 billion.

During the fourth quarter of 2025, the Company repurchased 1.4 million shares of its common stock for $471 million, at a weighted average price of $335.64, and paid a quarterly dividend of $1.71 per share, representing a distribution of cash totaling $377 million. As of December 31, 2025, the Company had approximately $6.7 billion of Board approved share repurchase authorization remaining.

abs_rxhxrgbxcxaligned.jpg wlp_rxhxrgbxcxaligned.jpg

Health Benefits is comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Employee Program businesses.

Health Benefits
Reportable Segment Highlights
(Unaudited)

(In billions)

Three Months Ended

Twelve Months Ended
December 31, 2025December 31, 2024December 31, 2025December 31, 2024

Operating Revenue1

$41.8$37.6$167.1$150.3

Operating Gain1,2

($0.2)$0.2$4.2$6.2

Adjusted Operating Gain1,3

($0.2)$0.2$4.2$6.3

Operating Margin1

(0.5%)0.6%2.5%4.2%

Adjusted Operating Margin1

(0.5%)0.6%2.5%4.2%

1.See “Basis of Presentation” on page 5 herein.

2.Operating Gain for the three and twelve months ended December 31, 2024 includes items that are excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.

3.Adjusted Operating Gain for three and twelve months ended December 31, 2024 excludes $16 and $66 million, respectively, of 2024 business dispositions and related items adjusted out of adjusted shareholders' net income for the Health Benefits segment.

Health Benefits segment operating revenue was $41.8 billion in the fourth quarter of 2025, an increase of $4.3 billion, or 11 percent compared to the fourth quarter of 2024. Operating revenue was $167.1 billion in 2025, an increase of $16.8 billion, or 11 percent. The increases for the quarter and year were driven primarily by higher premium yields, contributions from acquisitions, and growth in our Medicare Advantage membership, partially offset by membership attrition in our Medicaid business.

The Company reported an adjusted operating loss of $0.2 billion in the fourth quarter of 2025 and an adjusted operating gain of $4.2 billion for the full year. Adjusted operating results in both periods were impacted primarily by higher medical cost trend.

Medical membership totaled approximately 45.2 million as of December 31, 2025, a decrease of 0.5 million, or 1 percent, year over year, driven by attrition in our Medicaid business.

image.jpg

Carelon is comprised of CarelonRx and Carelon Services.

Carelon
Reportable Segment Highlights
(Unaudited)

(In billions)

Three Months Ended

Twelve Months Ended
December 31, 2025December 31, 2024December 31, 2025December 31, 2024

Operating Revenue1,2

$18.7$14.7$71.7$53.9

Operating Gain1,3

$0.6$0.6$3.4$2.9

Adjusted Operating Gain1,4,5

$0.6$0.6$3.4$3.1

Operating Margin1

3.1%3.9%4.7%5.4%

Adjusted Operating Margin1

3.3%4.4%4.8%5.8%

1.See “Basis of Presentation” on page 5 herein.

2.Operating revenue for the three and twelve months ended December 31, 2024 includes $0.2 and $0.8 billion, respectively, of revenue related to 2024 business dispositions and related items that have been excluded from adjusted operating gain.

3.Operating Gain for the three and twelve months ended December 31, 2025, and December 31, 2024, includes items that are excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.

4.Adjusted Operating Gain for three and twelve months ended December 31, 2025 excludes $38 million of 2025 business dispositions and related items adjusted out of adjusted shareholders' net income for the Carelon segment.

5.Adjusted Operating Gain for the three and twelve months ended December 31, 2024 excludes $74 and $215 million, respectively, of 2024 business dispositions and related items adjusted out of adjusted shareholders' net income for the Carelon segment.

Operating revenue for Carelon was $18.7 billion in the fourth quarter of 2025, an increase of $3.9 billion, or 27 percent compared to the prior year period, driven by growth in CarelonRx product revenue, the expansion of Carelon Services risk-based solutions, and the acquisition of CareBridge. Operating revenue was $71.7 billion in 2025, an increase of $17.8 billion, or 33 percent.

Adjusted operating gain for Carelon totaled $0.6 billion in the fourth quarter, approximately flat year over year. On a full year basis, adjusted operating gain was $3.4 billion in 2025, an increase of $0.3 billion, or 10 percent, driven by improved CarelonRx performance and growth in Carelon Services risk-based solutions.

Quarterly Dividend

On January 27, 2026, the Audit Committee of the Company's Board of Directors declared a first quarter 2026 dividend to shareholders of $1.72 per share. The first quarter dividend is payable on March 25, 2026 to shareholders of record at the close of business on March 10, 2026.

About Elevance Health

Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 104 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

Conference Call and Webcast

Management will host a conference call and webcast today at 8:30 a.m. Eastern Standard Time (“EST”) to discuss the company’s fourth quarter and full year 2025 results and 2026 outlook. The conference call should be accessed at least 15 minutes prior to the start of the call with the following numbers:

888-947-9963 (Domestic)

888-566-0046 (Domestic Replay)

312-470-0178 (International)

203-369-3677 (International Replay)

The access code for today's conference call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EST today, until the end of the day on February 27, 2026. The call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link. A webcast replay will be available following the call.

Basis of Presentation

1.Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets, gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Refer to pages 13 and 14 for the GAAP reconciliation tables.

2.Operating margin is defined as operating gain divided by operating revenue.

Elevance Health Contacts:

Investor Relations

Media
Nathan RichLeslie Porras

Investor.Relations@elevancehealth.com

Leslie.Porras@elevancehealth.com

Elevance Health

Earnings Release Financial Schedules and Supplementary Information Quarter & Year Ended December 31, 2025 •Membership and Other Metrics •Quarterly & Full Year Consolidated Statements of Income •Condensed Consolidated Balance Sheet •Condensed Consolidated Statement of Cash Flows •Supplemental Financial Information - Reportable Segments •Supplemental Financial Information - Reconciliation of Medical Claims Payable •Reconciliation of Non-GAAP Financial Measures •Financial Guidance Summary •Membership Guidance Summary

Elevance Health

Membership and Other Metrics
(Unaudited)
Change from
Medical Membership (in thousands)December 31,
2025
December 31,
2024
September 30,
2025
December 31,
2024
September 30,
2025
Individual1,307 1,287 1,354 1.6%(3.5%)
Employer Group Risk-Based3,617 3,713 3,616 (2.6%)—%
Commercial Risk-Based4,924 5,000 4,970 (1.5%)(0.9%)

BlueCard®

6,509 6,630 6,394 (1.8%)1.8%
Employer Group Fee-Based20,583 20,569 20,608 0.1%(0.1%)
Commercial Fee-Based27,092 27,199 27,002 (0.4%)0.3%
Medicare Advantage2,230 2,066 2,245 7.9%(0.7%)
Medicare Supplement882 891 877 (1.0%)0.6%
Total Medicare3,112 2,957 3,122 5.2%(0.3%)
Medicaid8,500 8,917 8,645 (4.7%)(1.7%)

Federal Employee Program

1,604 1,661 1,630 (3.4%)(1.6%)
Total Medical Membership45,23245,73445,369(1.1%)(0.3%)
Other Metrics (in millions)
CarelonRx Quarterly Adjusted Scripts88.5 82.9 85.0 6.8%4.1%
Carelon Services Consumers Served91.8 101.1 97.6(9.2%)(5.9%)

Elevance Health

Consolidated Statements of Income

(Unaudited)
(In millions, except per share data)Three Months Ended 
 December 31
Twelve Months Ended 
 December 31
20252024Change20252024Change
Revenues

Premiums

$40,690$36,24512.3%$164,639$144,16614.2%
Product revenue6,4606,714(3.8%)24,47022,6308.1%
Service fees2,1612,0306.5%8,4758,4080.8%
Total operating revenue49,31144,9899.6%197,584175,20412.8%
Net investment income493527(6.5%)2,1942,0517.0%
Net losses on financial instruments(57)(74)NM(653)(445)NM

Gain on sale of business

——NM—201NM
Total revenues49,74745,4429.5%199,125177,01112.5%
Expenses
Benefit expense38,06533,50013.6%148,223127,56716.2%
Cost of products sold5,5226,012(8.2%)21,17819,7507.2%
Operating expense5,4154,80412.7%20,98420,0254.8%
Interest expense3663407.6%1,4021,18518.3%
Amortization of other intangible assets164180(8.9%)6285808.3%
Total expenses49,53244,83610.5%192,415169,10713.8%
Income before income tax expense215606(64.5%)6,7107,904(15.1%)
Income tax expense (benefit)(331)193NM1,0491,933(45.7%)
Net income54641332.2%5,6615,971(5.2%)
Net loss attributable to noncontrolling interests15NM19NM
Shareholders' net income$547$41830.9%$5,662$5,980(5.3%)

Shareholders' earnings per diluted share

$2.47$1.8136.5%$25.21$25.68(1.8%)
Diluted shares221.8231.1(4.0%)224.6232.9(3.6%)
Benefit expense as a percentage of premiums93.5%92.4%110 bp90.0%88.5%150 bp
Operating expense as a percentage of total operating revenue11.0%10.7%30 bp10.6%11.4%(80)bp
Income before income tax expense as a percentage of total revenue0.4%1.3%(90)bp3.4%4.5%(110)bp

"NM" = calculation not meaningful

Elevance Health

Condensed Consolidated Balance Sheet

(In millions)December 31,
2025
December 31,
2024
Assets(Unaudited)
Current assets:
Cash and cash equivalents$9,491$8,288
Fixed maturity and equity securities26,624 26,393 
Premium and other receivables21,542 19,071 
Other current assets5,344 4,700 
Assets held for sale— 490 
Total current assets63,00158,942
Long-term investments11,960 10,784 
Property and equipment, net4,679 4,652 
Goodwill and other intangible assets39,544 40,371 
Other noncurrent assets2,310 2,140 
Total assets$121,494$116,889
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable$17,084$15,746
Short-term borrowings150 365 
Current portion of long-term debt1,099 1,649 
Other current liabilities22,702 22,668 

Liabilities held for sale

— 153 
Total current liabilities41,03540,581
Long-term debt, less current portion30,797 29,218 
Other noncurrent liabilities5,636 5,664 
Total liabilities77,46875,463
Total shareholders’ equity43,88241,315
Noncontrolling interests144 111 
Total equity44,02641,426
Total liabilities and equity$121,494$116,889

Elevance Health

Condensed Consolidated Statement of Cash Flows

(Unaudited)
(In millions)Twelve Months Ended December 31
20252024
Operating activities
Net income$5,661 $5,971 
Depreciation and amortization1,546 1,393 
Share-based compensation276 191 
Changes in operating assets and liabilities(3,680)(1,719)
Other non-cash items487 (28)
Net cash provided by operating activities4,2905,808
Investing activities
Proceeds from sale of investments, net of maturities69 586 

Net purchases of subsidiaries, net of cash acquired/sold

88 (4,446)
Purchases of property and equipment(1,116)(1,256)
Other, net(385)(51)
Net cash used in investing activities(1,344)(5,167)
Financing activities
Net change in short-term and long-term borrowings629 6,200 
Repurchase and retirement of common stock(2,605)(2,900)
Cash dividends(1,529)(1,508)
Other, net1,767 (599)
Net cash provided by (used in) financing activities(1,738)1,193
Effect of foreign exchange rates on cash and cash equivalents(5)(6)
Change in cash and cash equivalents1,2031,828
Cash and cash equivalents at beginning of period8,2886,526
Cash and equivalents included in assets held for sale at end of period—(66)
Cash and cash equivalents at end of period$9,491$8,288

REPORTABLE SEGMENTS

Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Employee Program businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as well as corporate expenses not allocated to our other reportable segments).

Elevance Health
Reportable Segment Details
(Unaudited)
(In millions)Three Months Ended December 31Twelve Months Ended December 31
20252024Change20252024Change
Operating Revenue
Health Benefits$41,835$37,58011.3%$167,094$150,27511.2%
CarelonRx11,6449,97716.7%43,40035,96120.7%
Carelon Services7,0154,76947.1%28,31617,96157.7%
Corporate & Other(83)(14)

NM6

46330949.8%
Eliminations(11,100)(7,323)

NM6

(41,689)(29,302)

NM6

Total Operating Revenue1

$49,311$44,9899.6%$197,584$175,20412.8 %
Operating Gain (Loss)

Health Benefits2

($220)$207

NM6

$4,158$6,243(33.4%)

CarelonRx3

72453335.8%2,4182,17211.3%

Carelon Services2,3

(150)35

NM6

96071733.9%

Corporate & Other2,3

(45)(102)

NM6

(337)(1,270)

NM6

Total Operating Gain1,4

$309$673(54.1%)$7,199$7,862(8.4%)
Operating Margin
Health Benefits(0.5%)0.6%(110) bp2.5%4.2%(170) bp
CarelonRx6.2%5.3%90 bp5.6%6.0%(40) bp
Carelon Services(2.1%)0.7%(280) bp3.4%4.0%(60) bp

Total Operating Margin1

0.6%1.5%(90) bp3.6%4.5%(90) bp
Health Benefits Revenue Details
(In millions)Three Months Ended December 31Twelve Months Ended December 31
20252024Change20252024Change
Health Benefits Operating Revenue
Commercial$12,747$11,8517.6%$50,401$46,8167.7%

Individual5

2,2482,1176.2%9,2958,29512.1%
Medicare10,7629,05418.9%44,75236,79521.6%
Medicaid14,50012,75513.7%56,62051,9379.0%
Federal Employee Program3,8263,920(2.4%)15,32114,7274.0%

Total Health Benefits Operating Revenue1

$41,835$37,58011.3%$167,094$150,27511.2%

1.See “Basis of Presentation” on page 5 herein.

2.Operating Gain for the three and twelve months ended December 31, 2024 included $90 and $281 million, respectively, of 2024 business dispositions and related items; including $74 and $215 million, respectively, for the Carelon Services segment; and $16 and $66 million, respectively, for the Health Benefits segment. Operating Gain for the three and twelve months ended December 31, 2024 included $66 and $224 million, respectively, of transaction and integration related costs, $12 and $692 million, respectively, of litigation and settlement expenses, and $0 and $268 million, respectively, of business optimization charges, all of which reside in the Corporate & Other reportable segment.

3.Operating Gain for the three and twelve months ended December 31, 2025 included $41 million of 2025 business dispositions and related items; including $45 million for the CarelonRx segment; ($7) million for the Carelon Services segment; and $3 million for the Corporate & Other segment. Operating Gain for the three and twelve months ended December 31, 2025 included $54 and $236 million, respectively, of transaction and integration related costs, $5 and $24 million, respectively, of litigation and settlement expenses, and ($34) and ($38) million, respectively, of business optimization charges, all of which reside in the Corporate & Other reportable segment.

4.Operating Gain for the three and twelve months ended December 31, 2025, and December 31, 2024, included items excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.

5.The Individual business, including ACA products, is reported as part of Commercial Operating Revenue.

6."NM" = calculation not meaningful.

Elevance Health

Reconciliation of Medical Claims Payable
Years Ended December 31
202520242023
(In millions)(Unaudited)
Gross medical claims payable, beginning of year$15,580 $15,865 $15,348 
Ceded medical claims payable, beginning of year(13)(7)(6)
Net medical claims payable, beginning of year15,567 15,858 15,342 
Business combinations and purchase adjustments344 143 — 
Net incurred medical claims:
Current year145,566 125,370 121,798 

Prior years redundancies1

(1,290)(1,731)(1,571)
Total net incurred medical claims144,276 123,639 120,227 
Net payments attributable to:
Current year medical claims130,265 110,930 107,146 
Prior years medical claims13,141 13,143 12,565 
Total net payments143,406 124,073 119,711 
Net medical claims payable, end of year16,781 15,567 15,858 
Ceded medical claims payable, end of year48 13 7 

Gross medical claims payable, end of year2

$16,829 $15,580 $15,865 

Current year medical claims paid as a percentage of current year net incurred medical claims

89.5 %88.5%88.0%

Prior year redundancies in the current year as a percentage of prior year net medical claims payable less prior year redundancies in the current year

9.0 %12.3%11.4%

Prior year redundancies in the current year as a percentage of prior year net incurred medical claims

1.0 %1.4%1.4%

1.Negative amounts reported for net incurred medical claims related to prior years result from claims being settled for amounts less than originally estimated.

2.Excludes insurance lines other than short duration.

Elevance Health

GAAP Reconciliation

(Unaudited)

This document references non-GAAP measures, including “Adjusted Shareholders’ Net Income,” “Adjusted Shareholders’ Net Income Per Share,” “Adjusted EPS,” “Adjusted Operating Gain,” “Adjusted Operating Expense” and “Adjusted Operating Expense Ratio,” which are non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP are available below. In addition to these non-GAAP measures, references are made to the measures “Operating Revenue” and “Operating Gain/Loss,” “Operating Margin” and “Adjusted EPS”. Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reportable segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Each of these measures is provided to further aid investors in understanding and analyzing Elevance Health’s operating and financial results. A reconciliation of Operating Revenue to Total Revenue is set forth in the Consolidated Statements of Income herein. A reconciliation of the non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP, together with a reconciliation of reportable segments operating gain to income before income tax expense, is provided below. Prior amounts may be grouped differently to conform to the current presentation. Net adjustment items per share may not sum due to rounding. A reconciliation of Operating Revenue to Total Revenue is set forth in the Consolidated Statements of Income herein.

Three Months Ended December 31Twelve Months Ended December 31
(In millions, except per share data)20252024Change20252024Change
Shareholders' net income$547$41830.9%$5,662$5,980(5.3%)
Add / (Subtract):

Amortization of other intangible assets

164 180 628 580 
Net losses on financial instruments57 74 653 445 

Transaction and integration related costs1

54 66 236 224 

Business dispositions and related items2

41 90 41 281 

Litigation and settlement expenses1

5 12 24 692 

Gain on sale of business

— — — (201)

Business optimization charges1

(34)— (38)268 
Tax impact of non-GAAP adjustments(95)(93)(402)(575)
Net adjustment items192 329 1,142 1,714 
Adjusted shareholders' net income$739$747(1.1%)$6,804$7,694(11.6%)
Shareholders' earnings per diluted share$2.47$1.8136.5%$25.21$25.68(1.8%)
Add / (Subtract):

Amortization of other intangible assets

0.74 0.78 2.80 2.49 

Net losses on financial instruments

0.26 0.32 2.91 1.91 

Transaction and integration related costs1

0.24 0.29 1.05 0.96 

Business dispositions and related items2

0.18 0.39 0.18 1.21 

Litigation and settlement expenses1

0.02 0.05 0.11 2.97 

Gain on sale of business

— — — (0.86)

Business optimization charges1

(0.15)— (0.17)1.15 
Tax impact of non-GAAP adjustments(0.43)(0.40)(1.79)(2.47)
Net adjustment items0.86 1.42 5.08 7.36 

Adjusted shareholders' earnings per diluted share

$3.33$3.233.1%$30.29$33.04(8.3%)
Three Months Ended December 31Twelve Months Ended December 31
(In millions)20252024Change20252024Change
Income before income tax expense$215$606(64.5%)$6,710$7,904(15.1%)
Net investment income(493)(527)(2,194)(2,051)

Gain on sale of business

— — — (201)
Net losses on financial instruments57 74 653 445 
Interest expense366 340 1,402 1,185 
Amortization of other intangible assets164 180 628 580 
Reportable segments operating gain$309$673(54.1%)$7,199$7,862(8.4%)

1.Adjustment item resides in the Corporate & Other reportable segment.

2.Adjustment item resides in the Health Benefits, CarelonRx, Carelon Services, and Corporate & Other reportable segments.

Elevance Health

GAAP Reconciliation

(Unaudited)

Three Months Ended December 31Twelve Months Ended December 31
(In millions)20252024Change20252024Change
Reportable segments operating gain$309$673(54.1%)$7,199$7,862(8.4%)
Add / (Subtract):

Transaction and integration related costs1

54 66 236 224 

Business dispositions and related items2

41 90 41 281 

Litigation and settlement expenses1

5 12 24 692 

Business optimization charges1

(34)— (38)268 

Net adjustment items

66 168 263 1,465 
Reportable segments adjusted operating gain$375$841(55.4%)$7,462$9,327(20.0%)
Three Months Ended December 31Twelve Months Ended December 31
(In millions)20252024Change20252024Change
Operating expense$5,415$4,80412.7%$20,984$20,0254.8%
Add / (Subtract):

Transaction and integration related costs1

(54)(66)(236)(224)

Business dispositions and related items2

(41)(90)(41)(281)

Litigation and settlement expenses1

(5)(12)(24)(692)

Business optimization charges1

34 — 38 (268)
Net adjustment items(66)(168)(263)(1,465)
Adjusted operating expense$5,349$4,63615.4%$20,721$18,56011.6%
Operating revenue$49,311$44,9899.6%$197,584$175,20412.8%
Operating expense ratio11.0 %10.7 %30 bp10.6 %11.4 %(80) bp
Adjusted operating expense ratio10.8 %10.3 %50 bp10.5 %10.6 %(10) bp

Full Year 2026 Outlook

Shareholders' earnings per diluted shareAt least $22.30
Add / (Subtract):

Amortization of other intangibles3

$2.00 

Net losses on financial instruments3

$1.15 

Transaction and integration related costs1,3

$0.90 

Litigation and settlement expenses1,3

$0.10 

Tax impact of non-GAAP adjustments3

Approximately ($0.95)

Net adjustment items$3.20 
Adjusted shareholders' earnings per diluted shareAt least $25.50

1.Adjustment item resides in the Corporate & Other reportable segment.

2.Adjustment item resides in the Health Benefits, CarelonRx, Carelon Services, and Corporate & Other reportable segments.

3.Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount.

Elevance Health

Financial Guidance Summary
(Unaudited)

Full Year 2025 Actual

Full Year 2026 Outlook

Premium Revenue

$164.6 billion

Mid single digit decline

Product Revenue

$24.5 billion

Mid single digit growth

Service Fees

$8.5 billion

Mid single digit growth

Total Operating Revenue

$197.6 billion

Low single digit decline
Benefit Expense Ratio90.0%90.2% +/- 50 bps

Adjusted Operating Expense Ratio

10.5%10.6% +/- 50 bps

Adjusted Operating Gain

$7.5 billion

At least $6.8 billion

Other Pre-Tax Items:
Net Investment income

$2,194 million

$1,875 million
Interest Expense

($1,402) million

($1,530) million
Amortization of Intangible Assets($628) million

($440) million

Adjusted Effective Tax Rate

17.6%22.0% - 24.0%

GAAP Diluted EPS

$25.21At least $22.30

Adjusted Diluted EPS

$30.29

At least $25.50

Diluted Shares

224.6 million

219-220 million

Operating Cash Flow

$4.3 billion

At least $5.5 billion

Segment Level Guidance Metrics
Operating Revenue Growth Rate
Health Benefits

$167.1 billion

Low single digit decline
CarelonRx

$43.4 billion

Low single digit growth
Carelon Services

$28.3 billion

Low single digit growth

GAAP Operating Margin vs. 2025

Health Benefits

2.5%

(50) - (25) bps
CarelonRx

5.6%

(25) - 0 bps
Carelon Services

3.4%

0 - 25 bps

Elevance Health

Membership Guidance Summary

(Unaudited)

Full Year 2025 Actual

Full Year 2026 Outlook

Year-End Medical Enrollment (in 000s)

Commercial Fee-Based

27,09227,200 - 27,500

Commercial Risk-Based

4,924

4,150 - 4,250

Medicaid

8,5007,650 - 7,850

Medicare Advantage

2,230

1,775 - 1,875

Medicare Supplement

882Approximately 850

Federal Employee Program

1,604Approximately 1,550
Fee-Based27,09227,200 - 27,500
Risk-Based18,140

15,975 - 16,375

Total45,232

43,175 - 43,875

Forward-Looking Statements

This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan,” “potential,” “predict” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems; failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity or sentiment related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

Source: Elevance Health, Inc.. This release was filed with the U.S. Securities and Exchange Commission on Jan 28, 2026 and is reproduced here as issued. View the filing.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.